Skip to main content
SpringerLink
Log in

Thrombocytopenia and Platelet Transfusions in Patients With Cancer

  • Chapter
Hematopoietic Growth Factors in Oncology

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 163 Accesses

Abstract

Use of intensive chemotherapy regiments in oncology and in bone marrow/progenitor cell transplantation programs has increased the demand for platelet products, particularly in patients with severe thrombocytopenia or bleeding complications. Use of apheresis platelet transfusions has also increased substantially, from 365,000 units in 1989 to 1,264,000 units in 2001 (Table 1) (1–3). This increase is being driven partly by the need for alternative platelet inventories to support cardiac surgery, oncology, and peripheral blood progenitor cell (PBPC) transplantation programs and partly by use of leukoreduced platelet products (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35: 802–812.

    Article  PubMed  CAS  Google Scholar 

  2. Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998; 38: 625–636.

    Article  PubMed  CAS  Google Scholar 

  3. National Blood Data Resource Center. Comprehensive Report on Blood Collection and Transfusion in the United States in 2001. Bethesda, MD: National Blood Data Resource Center. 2003.

    Google Scholar 

  4. Pall Corp. Demand leukocyte-depleted blood for more complete patient protection. Ann Thorac Surg 1997; 60: A20 - A21.

    Google Scholar 

  5. Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitzngel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vox Sang 1999; 77: 24–32.

    Article  PubMed  CAS  Google Scholar 

  6. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine, first of two parts-blood transfusion. N Engl J Med 1999; 340: 438–447.

    Article  PubMed  CAS  Google Scholar 

  7. Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982–1991. Transfusion 1993; 33: 890–893.

    Article  PubMed  CAS  Google Scholar 

  8. Dodd RY, Notari ED, Stramer SL. Current prevalence and incidence of infectious markers and estimated window-period risk in the American Red Cross donor population. Transfusion 2002; 42: 975–979.

    Article  PubMed  CAS  Google Scholar 

  9. Stevens CE, Aach RD, Hollinger FB, et al. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med 1984; 101: 733–738.

    PubMed  CAS  Google Scholar 

  10. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A and non-B hepatitis. N Engl J Med 1989; 321: 1494–1500.

    Article  PubMed  CAS  Google Scholar 

  11. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423–35.

    Article  PubMed  CAS  Google Scholar 

  12. Corash L, Behrman B, Rheinschmidt M, et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates. Blood 1997; 90: 267a.

    Google Scholar 

  13. McCullough J, Vesole D, Benjamin RJ, Slichter S, Pineda A, Snyder E, et al. Pathogen-inactivated platelets using HelinxTM Technology are hemostatically effective in the thrombocytopenia patient. Blood 2001; 98: 45A.

    Google Scholar 

  14. Sayers MH, Anderson KC, Goodnough LT, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116: 55–62.

    PubMed  CAS  Google Scholar 

  15. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV)-seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598–3603.

    PubMed  CAS  Google Scholar 

  16. Rubie H, Attal M, Campardou AM, et al. Risk factors for cytomegalovirus in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993; 11: 209–214.

    PubMed  CAS  Google Scholar 

  17. Vij R, Adkins D, Brown R, et al. Risk factors for cytomegalovirus (CMV) viremia post related donor allogeneic peripheral blood stem cell transplantation. Blood 1999; 94: 374b.

    Google Scholar 

  18. Wingard JR, Sostrin MB, Vriessendorp HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46: 61–65.

    Article  PubMed  CAS  Google Scholar 

  19. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029–4035.

    PubMed  CAS  Google Scholar 

  20. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of leukoreduction: a consensus statement. Transfusion 2001; 41: 560–569.

    Article  PubMed  CAS  Google Scholar 

  21. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood 1996; 87: 4910.

    PubMed  CAS  Google Scholar 

  22. Goodnough LT. The case against universal WBC (and for the practice of evidence-based medicine). Transfusion 2000; 40: 1522–1527.

    Article  PubMed  CAS  Google Scholar 

  23. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med 1992; 117: 151–162.

    PubMed  CAS  Google Scholar 

  24. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982; 42: 318–321.

    Article  PubMed  CAS  Google Scholar 

  25. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861–1869.

    Article  Google Scholar 

  26. Goodnough LT, Riddell J, Lazarus H, et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65: 103–107.

    Article  PubMed  CAS  Google Scholar 

  27. Uhlman EJ, Isriggs E, Walhermfechtel M, Goodnough LT. Pre-storage universal WBC of RBC units does not affect the incidence of transfusion reactions. Ttransfusion 2001; 41: 997–1000.

    Article  Google Scholar 

  28. Dzik WH, Anderson JK, O Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized trial of universal WBC reduction. Transfusion 2002; 42: 1114–1122.

    Article  PubMed  CAS  Google Scholar 

  29. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39: 665–670.

    Article  PubMed  CAS  Google Scholar 

  30. Ober C, Karrison T, Odem RR, et. al. Mononuclear-cell immunization in prevention of recurrent miscarriages: a randomized trial. Lancet 1999; 354: 365–369.

    Article  PubMed  CAS  Google Scholar 

  31. Opelz G, Terasaki PI: Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299: 799–803.

    Article  PubMed  CAS  Google Scholar 

  32. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175–186.

    Article  PubMed  CAS  Google Scholar 

  33. Bernstein SH, Nadermanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91: 3509–3517.

    PubMed  CAS  Google Scholar 

  34. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870–1875.

    Article  PubMed  CAS  Google Scholar 

  35. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601–3606.

    PubMed  CAS  Google Scholar 

  36. Menitove JE, ed. Standards for Blood Banks and Transfusion Services. Bethesda, MD: American Association of Blood Banks. 1999.

    Google Scholar 

  37. Goodnough LT, Ali S, Despotis GJ, Dynis M, DiPersio JF. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy. Vox Sang 1999; 76: 43–49.

    Article  PubMed  CAS  Google Scholar 

  38. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronic platelet transfusion dependent patient. Transfusion 1998; 38: 637–644.

    Article  PubMed  CAS  Google Scholar 

  39. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for fixed platelet requirements. Blood 1985; 66: 1105–1109.

    PubMed  CAS  Google Scholar 

  40. Klumpp TR, Herman JH, Gaughan JP, et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized double-blind trial. Transfusion 1999; 39: 674–681.

    Article  PubMed  CAS  Google Scholar 

  41. Norol F, Bierling P, Roudot-Throvac F, et al. Platelet transfusion: a dose-response study. Blood 1998; 92: 1448–1453.

    PubMed  CAS  Google Scholar 

  42. Ishida A, Handa M, Wakui M, Okamota S, Kamakuva M, Ikeda Y. Clinical factors influencing post-transfusion platelet increment in patients undergoing hematopoietic pregenitor cell transplantation-a prospective analysis. Transfusion 1998; 38: 839–847.

    Article  PubMed  CAS  Google Scholar 

  43. Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D. Thrombopoiesis and Thrombopoietins. Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, NJ: Humana. 1997.

    Google Scholar 

  44. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457–3469.

    Article  PubMed  CAS  Google Scholar 

  45. Paul SR, Bennett F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87: 7512–7516.

    Article  PubMed  CAS  Google Scholar 

  46. Yin TG, Schendel P, Yang YC. Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 1992; 175: 211–216.

    Article  PubMed  CAS  Google Scholar 

  47. Burnstein SA, Mei RL, Hentthron J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992; 153: 305–312.

    Article  Google Scholar 

  48. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992; 79: 327–331.

    PubMed  CAS  Google Scholar 

  49. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615–3624.

    PubMed  CAS  Google Scholar 

  50. Vredenburgh JJ, Hussein A, Fisher D, et al. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Transplant 1998; 4: 134–141.

    PubMed  CAS  Google Scholar 

  51. Tepler I, Elias L, Smith JW, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607–3614.

    PubMed  CAS  Google Scholar 

  52. Hokom MM, Lacey D, Kinstler O, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486–4492.

    PubMed  CAS  Google Scholar 

  53. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279–1281.

    Article  PubMed  CAS  Google Scholar 

  54. Basser RL, Rasko JEJ, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118–3128.

    PubMed  CAS  Google Scholar 

  55. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–409.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Lawrence T. Goodnough MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Amgen, Australia, Pty. Ltd., Monash University, Victoria, Australia

    George Morstyn MBBS, PhD, FRACP

  2. Amgen Inc., Thousand Oaks, CA, USA

    MaryAnn Foote PhD

  3. Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Australia

    Graham J. Lieschke MBBS, PhD, FRACP

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Goodnough, L.T. (2004). Thrombocytopenia and Platelet Transfusions in Patients With Cancer. In: Morstyn, G., Foote, M., Lieschke, G.J. (eds) Hematopoietic Growth Factors in Oncology. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-747-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-747-5_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9847-9

  • Online ISBN: 978-1-59259-747-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation